33 results about "CD23" patented technology

A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.

Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).

A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.

Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).

The invention provides a duplex-specific chimeric antigen receptor. The duplex-specific chimeric antigen receptor is composed of a signal peptide, two specific antigen binding fragments, an extra-membrane spacer region, a transmembrane region and an intracellular costimulatory signal region, wherein a first antigen which is recognized and bound by the specific antigen binding fragments is one of CD19, CD20, CD22, CD33, CD269, CD138, CD79a, CD79b, CD23, ROR1, CD30, a B cell surface antibody light chain, CD44, CD123, LewisY, CD7 or CD46; a second antigen which is recognized and bound by the specific antigen binding fragments is CD38; the two specific antigen binding fragments are connected through one connection peptide; the duplex-specific chimeric antigen receptor can be used for respectively recognizing two tumor-related antigens through constructing a low-affinity chimeric antigen receptor and a high-affinity chimeric antigen receptor and has very strong specificity. Furthermore, theinvention further provides application of the duplex-specific chimeric antigen receptor to tumor therapy.

The present invention provides compositions and methods for the treatment of asthma. The compositions can be, for example, siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.

Methods for inhibiting IgE production in a human subject using anti-CD23 antibodies.

A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.

The invention provides a bispecific chimeric antigen receptor, which consists of a signal peptide, two specific antigen-binding fragments, an extramembrane spacer, a transmembrane region, and an intracellular co-stimulatory signal region. The specific antigen-binding The first antigen recognized and bound by the fragment is CD19, CD20, CD22, CD33, CD269, CD138, CD79a, CD79b, CD23, ROR1, CD30, B cell surface antibody light chain, CD44, CD123, LewisY, CD7 or CD46 One: the second antigen recognized and bound by the specific antigen-binding fragment is CD38, and the two specific antigen-binding fragments are connected by a linking peptide, and the bispecific chimeric antigen receptor is receptored by constructing a low-affinity chimeric antigen receptor The body and high-affinity chimeric antigen receptors can recognize two tumor-associated antigens respectively with very strong specificity. In addition, the present invention also provides the application of the above-mentioned bispecific chimeric antigen receptor in the treatment of tumors.

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII / CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.